Shanghai Pharmaceuticals Holding Co. Ltd. Class A

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H carries a market capitalization of 8.15B, placing it among publicly traded companies globally. Its enterprise value stands at 10.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Pharmaceuticals Holding Co. Ltd. Class H's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H has 6.37B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H maintains a current ratio of 1.34, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H recorded 235.30M in income tax expense.

As of the close on September 15, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H's stock has declined approximately 8.21% over the past 52 weeks. The 50-day moving average sits at 1.29, while the 200-day moving average is 1.30.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H holds 5.93B in cash and equivalents against 6.84B in total debt, resulting in a net debt position of 1.71B. Total book value stands at 10.11B, with working capital of 6.19B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class H paid dividends of 0.04 per share.